Posters

      Aerosol from a candidate modified risk tobacco product has reduced effects on chemotaxis and transendothelial migration compared to smoke from conventional cigarettes

      van der Toorn, M.; Frentzel, S.; De Leon, H.; Goedertier, D.; Peitsch, M.; Hoeng, J.

      Conference date
      Nov 10, 2015
      Conference name
      American College of Toxicology (ACT) 2015
      Link to more information
      Link to more information
      Topic
      Summary

      Introduction: Cigarette smoking increases the risk of cardiovascular disease. Reduction in the levels of harmful constituents by heating rather than combusting tobacco without modifying the amount of delivered nicotine has the potential to reduce the risk of tobacco related disease. Aim: In this study, we investigated the effect of extract from a new candidate modified risk tobacco product (MRTP), the tobacco heating system (THS) 2.2, on the migratory behavior of monocytes in comparison with extract of smoke from combustible 3R4F reference cigarettes. Methods: The extracts were generated by aerosol-bubbling RPMI media from 3R4F and MRTP according to Health Canada standards. Endpoints included cytotoxicity (cell death assessed by 7-AAD staining followed by FACS analysis), inflammation (cytokine measurements), THP-1 cell migration (Boyden chambers), and transendothelial migration (TEM) determined by real-time impedance. Results: The results show that treatment of THP-1 cells with extract from 3R4F smoke or THS2.2 aerosol induced a concentration-dependent increase in cytotoxicity and inflammation (IL-8 and TNF-α secretion). The inhibitory effects of THS2.2 aerosol extract for chemotaxis and TEM were at least ~18 times less effective compared to 3R4F smoke extract. Furthermore, we found decreases in the integrity of a HCAEC monolayer in a concentration-dependent manner. However, for all other examined endpoints, the extract from 3R4F smoke showed more than one order of magnitude stronger effects than that from THS2.2 aerosol extract. Conclusion: These data indicate the potential of the Tobacco Heating System to reduce the risk for cardiovascular disease compared to combustible cigarettes. 

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.